GlassScriptPhysician profile
Jaren Lerner
NPI 1356839013
$9,637.23
in general payments reported to CMS, 2019-2025
52 companies · $2,578 in 2025
The $2,578 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,216 · 2023: $3,052 · 2024: $2,791 · 2025: $2,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,048 · Education: $249 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,047.60 |
| Education | $248.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,071.35 | 2022-2025 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $770.81 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Janssen Biotech, INC. | $621.97 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $564.16 | 2022-2025 | Calquence, Imfinzi, Lynparza |
| Genentech USA, INC. | $538.50 | 2022-2025 | Tecentriq, Phesgo, Polivy |
| E.R. Squibb & Sons, L.L.C. | $451.58 | 2022-2025 | Opdivo, Breyanzi, Opdualag |
| Merck Sharp & Dohme LLC | $435.87 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Stemline Therapeutics INC. | $393.98 | 2023-2025 | Orserdu |
| Abbvie INC. | $331.09 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $317.89 | 2023-2025 | |
| Pfizer INC. | $266.84 | 2023-2025 | |
| Eisai INC. | $242.02 | 2022-2024 | |
| Lilly USA, LLC | $238.73 | 2023-2024 | Jaypirca, Retevmo |
| Incyte Corporation | $231.73 | 2023-2025 | Monjuvi, Jakafi |
| Genzyme Corporation | $205.69 | 2023-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $202.92 | 2023-2025 | Libtayo |
| Seagen INC. | $170.58 | 2023 | Adcetris, Tukysa |
| Genmab U.S., INC. | $164.65 | 2023-2025 | Tivdak, Epkinly |
| Janssen Scientific Affairs, LLC | $149.82 | 2023 | Imbruvica, Darzalex, Tecvayli |
| Genentech, INC. | $143.85 | 2025 | Columvi |
| Kite Pharma, INC. | $141.84 | 2022-2025 | Yescarta |
| Acrotech Biopharma INC. | $136.73 | 2024 | Beleodaq |
| Emd Serono, INC. | $130.77 | 2022-2024 | Bavencio |
| Springworks Therapeutics, INC. | $125.00 | 2024 | Ogsiveo |
| Blueprint Medicines Corporation | $125.00 | 2023 | Ayvakit |
| Sobi, INC | $118.54 | 2022-2025 | |
| Amgen INC. | $114.98 | 2025 | Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $114.69 | 2024-2025 | Iclusig, Fruzaqla |
| Celgene Corporation | $104.34 | 2022-2025 | Reblozyl, Pomalyst |
| Exelixis INC. | $103.16 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $97.17 | 2024-2025 | Ultomiris |
| Astellas Pharma US INC | $86.57 | 2024-2025 | Xtandi, Vyloy, Xospata |
| Beigene USA, INC. | $75.74 | 2023-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $74.71 | 2022-2025 | |
| Adc Therapeutics America, INC. | $61.28 | 2022-2023 | |
| Puma Biotechnology, INC. | $51.60 | 2024-2025 | |
| Gilead Sciences, INC. | $49.99 | 2024 | Trodelvy |
| Agios Pharmaceuticals, INC. | $47.99 | 2024-2025 | Pyrukynd |
| Recordati_rare_diseases_inc. | $45.00 | 2024-2025 | Sylvant |
| Karyopharm Therapeutics INC. | $44.79 | 2022-2023 | Xpovio |
| Taiho Oncology, INC. | $32.49 | 2023-2024 | |
| Tempus Ai, INC | $29.79 | 2025 | Xt Cdx |
| G1 Therapeutics, INC. | $29.12 | 2022 | |
| Beone Medicines USA, INC. | $28.72 | 2025 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $25.00 | 2025 | Provenge |
| Apellis Pharmaceuticals, INC. | $24.88 | 2024 | Empaveli |
| Progenics Pharmaceuticals, INC. | $21.13 | 2024 | |
| Secura Bio, INC. | $18.46 | 2024 | Copiktra |
| Aveo Pharmaceuticals, INC. | $17.86 | 2025 | |
| Array Biopharma INC | $17.23 | 2024 | Mektovi, Tukysa, Braftovi |
| Emmaus Medical, INC. | $15.90 | 2025 | Endari |
| Mirati Therapeutics, INC. | $12.73 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaren Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.